The Effect of Virtual Reality Application on Independence and Hand Functions in Daily Life in Children With CP

March 12, 2024 updated by: Basak Karadag, Hacettepe University

The Effect of Virtual Reality Intervention on Upper Extremity Functioning and Perceived Independence in Daily Life in Children With Hemiplegic Cerebral Palsy

The aim of this study is to evaluate the effect of virtual reality applications on the level of independence and upper extremity functionality perceived by children in daily life in children with hemipegic cerebral palsy.

The research is a randomized controlled, cross-over study. The sample group of the research is children diagnosed with hemiplegic cerebral palsy and families who are receiving inpatient treatment in the pediatric service of Ankara City Hospital Physical Therapy and Rehabilitation Hospital.

Two groups, intervention (A) and control (B), will be created from the target research group using the randomization method.

The upper extremity functionality of both research groups before the intervention will be evaluated with the 'Motor Activity Diary for Children' scale and the perceived independence level with the 'Children's Hand Use Experience' scale.

After the initial evaluation is completed, group A, represented as the intervention group, will receive ArmeoSenso virtual reality intervention in the upper extremity hand function laboratory for 3 weeks, 5 days a week, each session for 30 minutes, in addition to traditional occupational therapy and physiotherapy rehabilitation programs. Meanwhile, group B, represented as the control group, will continue the traditional occupational therapy and physiotherapy rehabilitation program. At the end of the third week of the intervention, tests measuring upper extremity functionality and perceived independence level will be repeated.

Measurement tools will be repeated at the beginning of the intervention, at the end of the 3rd week, and at the end of the intervention.

Study Overview

Status

Not yet recruiting

Detailed Description

The sample group of the research is children between the ages of 6-12, diagnosed with hemiplegic cerebral palsy, who are receiving inpatient treatment in the pediatric service of Ankara City Hospital Physical Therapy and Rehabilitation Hospital, and their families.

Statistical power analysis was performed to calculate the number of people required to be included in the study. Statistical power analysis was performed with G*Power v.3.1.9.7 software. In the analysis, the Type 1 error margin (α) was accepted as 5% and the desired statistical power (1-β) was accepted as 0.80. In order to carry out the analysis, randomized controlled studies in the literature on the subject that reported effect sizes were examined. Studies have found that in virtual reality-based interventions applied to children with cerebral palsy, strong to very strong effect sizes were reported between intervention and control groups in variables such as upper extremity functions and performance in daily living activities (4, 7-11). When calculations were made using the strong effect size (Cohen's d = 0.80) in the sample size analysis, it was determined that the smallest sample size that needed to be reached for both groups was 26. Therefore, a total of 52 people were included in the study.

Study Type

Interventional

Enrollment (Estimated)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Ankara
      • Multiple Locations, Ankara, Turkey, 06000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • - Having a diagnosis of hemiplegic SP
  • Being between the ages of 6-12
  • Not having any fixed contracture in the upper extremity
  • According to the Modified Ashworth Scale, the upper extremity spasticity value is at the level of 1,1+,2 or 3
  • Being at level I, II or III according to the Gross Motor Function Classification System (GMFCS)
  • Being at level II or III according to the Manual Ability Classification System (MACS)
  • Being at level I, II or III according to the Communication Function Classification System (CFCS)
  • Being within the normal cognitive level according to the Modified Pediatrics Mini Mental Test score
  • Being at level I, II or III according to the Eating and Drinking Ability Classification System (EDACS)
  • Being at level I, II or III according to the Visual Function Classification System for Children with Cerabral Palsy (VFCS)
  • Volunteering to participate in the study

Exclusion Criteria:

  • Having botolinum toxin injection within the last 6 months
  • Having undergone a surgical procedure within the last 1 year
  • Fracture, trauma, etc. in the upper extremity. to live

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: ArmeoSenso
ArmeoSenso virtual reality application will be applied to group A in the 0-3 weeks of the study and to group B in the 3-6 weeks.
ArmeoSenso is an upper extremity virtual reality application with three motion sensors and one hand grip sensor. The device detects the person's body, arm, forearm and hand movements and displays the reflection of the movements on the screen. The application includes studies on upper extremity functions.
It includes traditional occupational therapy and physiotherapy approaches.
Other: Traditional rehabilitation
Traditional rehabilitation (physiotherapy and occupational therapy) approaches will continue to be applied to groups A and B at all stages of the research.
It includes traditional occupational therapy and physiotherapy approaches.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The effect of virtual reality applications on perceived independence in daily life in hemiplegic CP.
Time Frame: At the end of the 6th week
The independence levels perceived by children with hemiplegic CP in daily life will be evaluated with the Children's Hand Use Experience Questionnaire.
At the end of the 6th week
The effect of virtual reality applications on upper extremity functionality in daily life in children with hemiplegic CP.
Time Frame: At the end of the 6th week
The impact on the upper extremity functionality of children with hemiplegic CP in daily life will be evaluated with the Pediatric Motor Activity Log-Revised test.
At the end of the 6th week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dosimetry of virtual reality applications
Time Frame: At the end of the 6th week
As suggested in further research, examining the dosimetric properties of virtual reality applications such as frequency and duration and comparing them with other studies.
At the end of the 6th week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Başak Karadağ, MSc, Ankara Bilkent City Hospital
  • Study Director: Meral Huri, Professor, Hacettepe University
  • Principal Investigator: Berke Aras, Ass.Prof., Ankara Bilkent City Hospital
  • Study Chair: Özge Tezen, MD, Ankara Bilkent City Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 23, 2024

Primary Completion (Estimated)

June 29, 2024

Study Completion (Estimated)

October 29, 2024

Study Registration Dates

First Submitted

February 20, 2024

First Submitted That Met QC Criteria

March 12, 2024

First Posted (Actual)

March 19, 2024

Study Record Updates

Last Update Posted (Actual)

March 19, 2024

Last Update Submitted That Met QC Criteria

March 12, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Only the principal investigator can access information about individuals; other researchers will not be able to access this information due to blinding.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hemiplegic Cerebral Palsy

Clinical Trials on ArmeoSenso

3
Subscribe